CITIC Securities has released a research report initiating coverage on SHOUGANG LANZA (02553) with a "Buy" rating and a target price of HK$44, implying a 66.79% upside from the HK$26.38 level at the time of the report's publication. The brokerage projects the company's revenue to reach RMB 657 million, RMB 860 million, and RMB 1.546 billion for the fiscal years 2026, 2027, and 2028 respectively, driven by the gradual commissioning of new projects.

Positioned as a leading specialized and innovative player in AI-powered synthetic biology and CCUS, the company has faced near-term earnings pressure due to fluctuations in gas supply and ethanol prices. However, as product maturity improves and production capacity at its four major bases continues to recover, the company is leveraging its park-based gas supply projects to ease feedstock constraints while expanding through technology licensing models. Combined with the iterative upgrade of its first- and second-generation core technologies and supportive policy tailwinds, the company is advancing multiple new business pipelines, including SAF, green polyethylene, and bioactive peptides, which together underpin substantial long-term growth potential.